C-CAT: The National Datacenter for Cancer Genomic Medicine in Japan

82Citations
Citations of this article
35Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Since June 2019, under the umbrella of the national health insurance system, Japan has started cancer genomic medicine (CGM) with comprehensive genomic profiling (CGP) tests. The Ministry of Health, Labour and Welfare (MHLW) of Japan constructed a network of CGM hospitals (a total of 233 institutes as of July 1, 2022) and established the Center for Cancer Genomics and Advanced Therapeutics (C-CAT), the national datacenter for CGM. Clinical information and genomic data from the CGP tests are securely transferred to C-CAT, which then generates “C-CAT Findings” reports containing information of clinical annotation and matched clinical trials based on the CGP data. As of June 30, 2022, a total of 36,340 datapoints of clinical/genomic information are aggre-gated in C-CAT, and the number is expected to increase swiftly. The data are now open for sharing with not only the CGM hospitals but also other academic institutions and industries.

Cite

CITATION STYLE

APA

Kohno, T., Kato, M., Kohsaka, S., Sudo, T., Tamai, I., Shiraishi, Y., … Mano, H. (2022). C-CAT: The National Datacenter for Cancer Genomic Medicine in Japan. Cancer Discovery, 12(11), 2509–2515. https://doi.org/10.1158/2159-8290.CD-22-0417

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free